<DOC>
	<DOCNO>NCT02144415</DOCNO>
	<brief_summary>This single-center study single-dose , randomize , double-blind , placebo- active-controlled crossover study single inpatient treatment visit . The abuse potential single oral dos EB-1020 IR ( 400 mg , 800 mg ) compare placebo d-amphetamine ( 20 mg , 40 mg ; active control ) healthy recreational stimulant user . Subjects participate medical Screening visit ( Visit 1 ) , one 4-day inpatient Qualification Phase ( Visit 2 ) , one 11-day inpatient Treatment Phase ( Visit 3 ) , safety Follow-up visit ( Visit 4 ) .</brief_summary>
	<brief_title>A Study Evaluate Abuse Potential EB-1020 Immediate-Release Healthy Recreational Stimulant Users</brief_title>
	<detailed_description>Subjects randomize 1 10 treatment sequence accord two 5 x 5 William square design . To maintain blinding , subject require ingest eight capsule approximately 240 mL water study drug administration day . Serial pharmacodynamic ( PD ) evaluation conduct 24 hour study drug administration . Pharmacokinetic ( PK ) sample obtain confirm exposure EB-1020 . Safety monitor include record adverse event ( AEs ) , regular assessment vital sign measurement , 12-lead electrocardiogram ( ECG ) finding , continuous telemetry monitoring least 3 hour study drug administration .</detailed_description>
	<mesh_term>Amphetamine</mesh_term>
	<mesh_term>Lisdexamfetamine Dimesylate</mesh_term>
	<mesh_term>Dextroamphetamine</mesh_term>
	<criteria>1 . Subjects must healthy male nondependent recreational drug user 2 . Subjects must 18 55 year old , inclusive . 3 . Subjects must great equal 10 lifetime nontherapeutic experience central nervous system ( CNS ) stimulant ( e.g. , amphetamine , cocaine , methylphenidate ) , great equal 1 nontherapeutic use prescription stimulant within 12 month prior Screening , great equal 1 nontherapeutic use CNS stimulant within 12 week prior Screening . 1 . Subjects deem medically unsuitable unlikely comply study protocol reason . 2 . Subjects pass Qualification Phase criterion eligible Treatment Phase .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>abuse liability</keyword>
	<keyword>recreational drug user</keyword>
	<keyword>stimulant</keyword>
	<keyword>d-amphetamine</keyword>
	<keyword>ADHD</keyword>
</DOC>